Marker Therapeutics (MRKR) Short-term Investments (2021 - 2026)
Marker Therapeutics (MRKR) posted quarterly Short-term Investments of $700000.0 for Q1 2026, down 28.19% quarter-over-quarter from $974799.0 in Q4 2025.
Marker Therapeutics (MRKR) Short-term Investments (2021 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Short-term Investments for 4 consecutive years, with $700000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments changed N/A year-over-year to $700000.0; the TTM figure through Mar 2026 stood at $700000.0 (changed N/A YoY), while the FY2025 annual figure was $974799.0, changed N/A from the prior year.
- Short-term Investments retreated to $700000.0 in Q1 2026 per MRKR's latest filing, from $974799.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $1.4 million in Q2 2025 and bottomed at $181864.0 in Q1 2022.
- Historically, Short-term Investments has averaged $931332.6 across 3 years, with a median of $974799.0 in 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 974,799.00 |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2022 | 181,864.00 |
| Dec 31, 2021 | 1.15 Mn |